Exosomes derived from different sources of mesenchymal stem cells attenuate cisplatin-induced ovarian toxicity
Journal of Reproductive Immunology · 2026
DOI: 10.1016/j.jri.2026.104942 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Reproductive Immunology, 2026. Verfasst von Mengtian Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Research Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gyn…. Hauptthemen laut MEDLINE: Exosomes, Mesenchymal Stem Cells, Primary Ovarian Insufficiency, Induced Pluripotent Stem Cells. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Premature ovarian insufficiency (POI) poses significant challenges to reproductive health due to follicular depletion and hormonal dysregulation. Despite advances in stem cell therapy, clinical translation remains hindered by donor variability and ethical constraints. This study evaluates the therapeutic potential of exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells (iPSCMSC-exo) versus umbilical cord-derived MSC exosomes (hUCMSC-exo) for POI intervention. In vitro, both exosome types enhanced migration and tube formation of human umbilical vein endothelial cells (HUVECs), while iPSCMSC-exo additionally promoted proliferation. iPSCMSC-exo attenuated cisplatin-induced granulosa cell apoptosis, while both types suppressed p21-mediated cell cycle arrest. In the cisplatin-induced POI mouse model, exosome treatment effectively restored Follicle-stimulating hormone (FSH) levels. However, the therapeutic efficacy of exosomes in restoring anti-Müllerian hormone (AMH) levels and follicle counts was limited, as confirmed by synchrotron radiation microtomography revealing persistent structural depletion. Notably, iPSCMSC-exo demonstrated functional outcomes similar to hUCMSC-exo. The autologous origin and scalable production of iPSCMSCs address donor heterogeneity and supply limitations inherent to traditional MSC sources. Further optimization of targeted delivery systems is warranted to overcome biodistribution challenges and enhance structural regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Translational Research Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, Schoo…
- Molarray Biotechnology (Shanghai) Co., Ltd., Shanghai 200335, China.
- Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Henan International Joint Laboratory of Ovarian Malignancies, Zhengzhou 450052, China. Electronic address: wangbaojin@zzu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wei, M., Peng, H., Tian, H., Wei, Y., Jia, L., Li, H., Cheng, Wang, B., & Wang, K. (2026). Exosomes derived from different sources of mesenchymal stem cells attenuate cisplatin-induced ovarian toxicity. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2026.104942
Vancouver
Wei M, Peng H, Tian H, Wei Y, Jia L, Li H, et al. Exosomes derived from different sources of mesenchymal stem cells attenuate cisplatin-induced ovarian toxicity. Journal of Reproductive Immunology. 2026. doi:10.1016/j.jri.2026.104942
BibTeX
@article{Wei2026,
author = {Wei, Mengtian and Peng, Hao and Tian, Haojun and Wei, Yingying and Jia, Linyan and Li, Han and Cheng, De and Wang, Baojin and Wang, Kai},
title = {Exosomes derived from different sources of mesenchymal stem cells attenuate cisplatin-induced ovarian toxicity},
journal = {Journal of Reproductive Immunology},
year = {2026},
doi = {10.1016/j.jri.2026.104942}
}
EUVIMED